The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients
Open accessAbstract
Objective To compare the cumulative survival and event free survival in patients with Jo-1 versus non-Jo-1 anti-tRNA synthetase autoantibodies (anti-synAb). Methods Anti-synAb positive patients initially evaluated from 1985 to 2009 were included regardless of the connective tissue disease (CTD) diagnosis. Clinical data were extracted from a prospectively collected database and chart review. Survival between Jo-1 and non-Jo-1 was compared by log rank and Cox proportional hazards methods. Results 202 patients possessed anti-synAb: 122 Jo-1 and 80 non-Jo-1 (35 PL-12; 25 PL-7; 9 EJ; 6 KS; 5 OJ). The diagnoses at first visit for Jo-1 and non-Jo-1 patients were myositis in 83% and 40.0%, overlap or undifferentiated CTD in 17% and 47.5%, and systemic sclerosis in 0% and 12.5%, respectively (p<0.001). The median delay in diagnosis was 0.4 years in Jo-1 patients versus 1.0 year in non-Jo-1 patients (p<0.001). The most common causes of death in the overall cohort were pulmonary fibrosis in 49% and pulmonary hypertension in 11%. The 5- and 10-year unadjusted cumulative survival was 90% and 70% for Jo-1 patients, and 75% and 47% for non-Jo-1 patients (p<0.005). The hazard ratio (HR) of non-Jo-1 patients compared with Jo-1 patients was 1.9 (p=0.01) for cumulative and 1.9 (p=0.008) for event free survival from diagnosis. Age at first diagnosis and diagnosis delay but not gender, ethnicity and CTD diagnosis influenced survival. Conclusions Non-Jo-1 anti-synAb positive patients have decreased survival compared with Jo-1 patients. The difference in survival may be partly attributable to a delay in diagnosis in the non-Jo-1 patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polymyositis and Dermatomyositis: (First of Two Parts)
Bohan, A., & Peter, J. B. (1975) · New England Journal of Medicine · doi:10.1056/nejm197502132920706 · Cited by 5,059
Polymyositis and Dermatomyositis: (Second of Two Parts)
Bohan, A., & Peter, J. B. (1975) · New England Journal of Medicine · doi:10.1056/nejm197502202920807 · Cited by 2,447
Love, L. A., Leff, R. L., Fraser, D. D., Targoff, I. N., Dalakas, M., Plotz, P. H., & Miller, F. W. (1991) · Medicine · doi:10.1097/00005792-199111000-00002 · Cited by 969
Sato, S., Hirakata, M., Kuwana, M., Suwa, A., Inada, S., Mimori, T., Nishikawa, T., Oddis, C. V., & Ikeda, Y. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21023 · Cited by 747
Self-citationPolymyositis–Dermatomyositis-associated Interstitial Lung Disease
DOUGLAS, W. W., TAZELAAR, H. D., HARTMAN, T. E., HARTMAN, R. P., DECKER, P. A., SCHROEDER, D. R., & RYU, J. H. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2103110 · Cited by 557
Interstitial lung disease in polymyositis and dermatomyositis
Marie, I., Hachulla, E., Chérin, P., Dominique, S., Hatron, P. ‐., Hellot, M. ‐., Devulder, B., Herson, S., Levesque, H., & Courtois, H. (2002) · Arthritis Care & Research · doi:10.1002/art.10794 · Cited by 478
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality
Sultan, S. M., Ioannou, Y., Moss, K., & Isenberg, D. A. (2002) · Rheumatology · doi:10.1093/rheumatology/41.1.22 · Cited by 268
Hirakata, M., Suwa, A., Nagai, S., Kron, M. A., Trieu, E. P., Mimori, T., Akizuki, M., & Targoff, I. N. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2315 · Cited by 187
Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis
Mammen, A. L. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05119.x · Cited by 186
Autoantibody to U3 Nucleolar Ribonucleoprotein (Fibrillarin) In Patients with Systemic Sclerosis
Okano, Y., Steen, V. D., & Medsger, T. A. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350114 · Cited by 183
Cited by
Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis
Betteridge, Z., & McHugh, N. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12451 · Cited by 1,056
Idiopathic inflammatory myopathies
Lundberg, I. E., Fujimoto, M., Vencovsky, J., Aggarwal, R., Holmqvist, M., Christopher-Stine, L., Mammen, A. L., & Miller, F. W. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00321-x · Cited by 703
Self-citationSatoh, M., Tanaka, S., Ceribelli, A., Calise, S. J., & Chan, E. K. L. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8510-y · Cited by 420
McHugh, N. J., & Tansley, S. L. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.56 · Cited by 390
Current Classification and Management of Inflammatory Myopathies
Schmidt, J. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180308 · Cited by 324
Metadata
- Authors
- Aggarwal, R., Cassidy, E., Fertig, N., Koontz, D. C., Lucas, M., Ascherman, D. P., & Oddis, C. V.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 73
- Issue
- 1
- Pages
- 227-232
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2126188363
- Cited by
- 301
- References
- 17
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. https://app.cochat.ai/papers/10.1136/annrheumdis-2012-201800
- The paper
- Aggarwal, R., Cassidy, E., Fertig, N., Koontz, D. C., Lucas, M., Ascherman, D. P., & Oddis, C. V. (2014). Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2012-201800
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.